

Concomitant Presentation Of Adult Sjögren's Syndrome With Lupus Anticoagulant-Hypoprothrombinemia Syndrome: A Case Report

BinHan Liu, Yi Liu*

Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

***Correspondence to:**

Yi Liu,

Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

Tel.: +0086-15328075110

E-mail: yiliu_2020@scu.edu.cn

Received Date: 08 Nov 2023

Accepted Date: 24 Nov 2023

Published Date: 30 Nov 2023

Citation:

Yi Liu. Concomitant Presentation Of Adult Sjögren's Syndrome With Lupus Anticoagulant-Hypoprothrombinemia Syndrome: A Case Report. Journal Of Clinical Cases 2023.

1. Abstract

In the context of LAHS, a rare hemorrhagic disorder linked with systemic lupus erythematosus (SLE) and viral infections, we report an adult patient diagnosed with primary Sjögren's syndrome who later developed LAHS. The patient responded positively after undergoing steroid therapy and receiving the immunosuppressive agent cyclophosphamide. Remarkably, a 2-month follow-up revealed significant recovery. This case underscores the unique coexistence of Sjögren's syndrome and LAHS and the efficacy of the combined treatment approach.

2. Keywords:

Sjögren's syndrome, LAHS, factor II deficiency, lupus anticoagulant, steroids, cyclophosphamide.

3. Introduction

Lupus Anticoagulant-Hypoprothrombinemia Syndrome (LAHS) is a rare and intricate hemorrhagic disorder¹. It is characterized by the unique simultaneous occurrence of acquired factor II deficiency and lupus anticoagulant (LA) presence. Historically, the incidence of LAHS has been predominantly observed among children and women. Moreover, it often presents with systemic lupus erythematosus (SLE) and is intricately

linked with viral infections, adding complexity to its diagnosis and management². Sjögren's, on the other hand, is an autoimmune disease in which the immune system mistakenly attacks the glands that produce tears and saliva, leading to dry eyes and mouth. Its primary form, where the syndrome exists independently, is distinguishable from its secondary form, which coexists with other autoimmune diseases³. The coexistence of Sjögren's syndrome with other autoimmune disorders is not uncommon. However, its concurrence with LAHS has been sparsely documented, making it a topic of immense medical interest⁴.

The epidemiology of both conditions provides valuable insights. While Sjögren's syndrome affects an estimated 1-4 million people in the US alone, its prevalence is much higher in adults, especially women, and LAHS remains a rare phenomenon⁵. Previous research has individually delved into the etiopathogenesis, clinical features, and management strategies for both conditions. However, limited literature is available on the simultaneous presentation of both disorders, emphasizing the value of this case report in bridging that knowledge gap⁶. The interplay between autoimmune diseases is intricate and not entirely understood. Their combined presentation can pose diagnostic challenges and demand a multidimensional approach to treatment. In this context, the current report aims to shed light on a unique case where an adult patient with primary Sjögren's syndrome developed LAHS⁷. By exploring this intersection, this study endeavors to provide a comprehensive understanding of the potential overlaps, pathophysiological mechanisms, and therapeutic interventions pertinent to these conditions⁸. Understanding such cases is pivotal in light of the limited existing literature on the confluence of Sjögren's syndrome and LAHS⁹. It enriches the clinical and academic discourse and offers new avenues for therapeutic strategies. Furthermore, by elucidating the intricacies of this combined presentation, the medical community can be better equipped to manage similar cases in the future, ensuring optimized patient care¹⁰.

4. Case report

4.1. Chief Complaint: A 57-year-old female presented with a 13-year history of joint pain and complaints of gum bleeding and skin bruising for the past 3 months.

4.2. History of Present Illness: The patient first experienced joint pain 13 years ago, which has been persistent. For the last three months, she noticed gum bleeding and skin bruises without any evident cause. The patient had a previous medical history of cerebral infarction.

4.3. Physical Examination: On admission, ecchymosis was observed on both lower extremities and dental caries were present in the oral cavity. No other significant abnormalities were detected.

Laboratory Findings:

- Positive anti-nuclear antibodies with a titer of 1:320 show a granular and homogeneous pattern.
- The ENA profile revealed elevated anti-SS-A and anti-Ro-52 antibody levels, while anti-SS-B was lower.
- RF was 20.60 IU/mL, and the anti-CCP antibody was 15.40 U/mL.
- Positive Coombs test.
- Decreased complement levels of C3 and C4.
- ESR was elevated at 63.0 mm/h, and CRP was 7.06 mg/L.
- Positive phospholipid syndrome-related antibodies: ACAIgA 66.20 APLU/mL, ACA IgG >120.00 GPLU/mL, ACAIgM 64.20 MPLU/mL.
- Elevated levels of anti-β2GPI IgA, IgG, and IgM.

4.4. Additional Examinations: Salivary gland SPECT scan indicated impairment in both parotid and submandibular glands. Peripheral venous color Doppler ultrasound showed no thrombus formation. Diagnosis and Treatment: The patient did not meet the diagnostic criteria for rheumatoid arthritis (RA) due to the absence of significant joint symptoms. The revised diagnosis was “Sjogren’s syndrome; lupus anticoagulant-hypocoagulable syndrome”. Upon admission, the patient received 40mg of intravenous methylprednisolone daily, which led to a noticeable improvement in factor II activity. Subsequently, the patient was prescribed 50mg of oral cyclophosphamide daily for immune suppression and was successfully discharged.

Follow-up: A two-month follow-up at the outpatient clinic revealed significant improvement in factor II activity. The platelet count was $41 \times 10^9/L$, and all phospholipid syndrome-related antibodies tested positive. The patient will continue to be monitored closely, with plans to taper off the steroid dosage, evaluate the efficacy of cyclophosphamide, and explore new and effective treatment strategies.

5. Discussion

LAHS represents a less common coagulation disorder and an autoimmune disease characterized by lupus anticoagulants and diminished prothrombin levels¹¹. Lupus anticoagulants are a subset of autoantibodies that interrupt the routine clotting process, increasing predisposition to excessive blood clot formation¹². Conversely, hypoprothrombinemia is typified by the reduction in the levels of a crucial protein, prothrombin, within the coagulation system, which facilitates clot formation¹³. Clotting gets compromised when there’s a drop in prothrombin levels¹³. The precise etiology of LAHS remains enigmatic, but research points towards aberrant immune system functionality as a pivotal component in its pathogenesis¹⁴. In its aberrancy, the immune system produces antibodies that target the body’s clotting factors, disrupting the routine clotting cascade¹⁴. Clinically, this syndrome manifests as recurrent bouts of both

thrombosis and bleeding¹⁵. Patients may manifest with conditions like thrombotic venous inflammation, deep vein thrombosis, and pulmonary embolism¹⁶. Furthermore, owing to the diminished activity of clotting factors, patients may also manifest bleeding tendencies, such as skin ecchymosis, epistaxis, and menstrual irregularities¹⁵. In the tapestry of prior case reports or diminutive case series studies, LAHS appears to chiefly afflict children and women. It’s observed that the younger cohort is more likely to have associations with infections rather than autoimmune disorders¹⁷. However, among adults, LAHS frequently correlates with autoimmune diseases¹⁸. The primary manifestation of LAHS is bleeding, but a subset around 10% of patients, experience thrombotic events. These thrombotic events occur more in patients with LAHS and autoimmune disorders than in those with infections alone¹⁹. For LAHS spurred by viral infections, it’s conventionally believed to resolve autonomously within a set timeframe²⁰. Conversely, immune-mediated LAHS typically mandates immunosuppressive therapy²¹. The patient under our lens manifests a novel case of LAHS triggered by Sjögren’s syndrome, an erstwhile undocumented eventuality but still categorized under autoimmune disorders²².

At this juncture, no standardized therapeutic protocol or guideline is specifically tailored for LAHS²³. The consensus pivots around supportive care and immunosuppressive therapy²⁴. Corticosteroids emerge as the front-line therapeutic recourse, and the deployment of immunosuppressive agents becomes imperative for tapering down steroids²⁵. Additionally, there’ve been isolated case reports that spotlight the efficacy of other therapeutic modalities like cyclophosphamide, azathioprine, intravenous immunoglobulin, and rituximab^{26, 27, 28, 29}. It’s worth noting, however, that a subset of cases doesn’t register the anticipated therapeutic outcomes³⁰. In this vignette, the therapeutic regimen encompassing methylprednisolone and cyclophosphamide manifested a commendable therapeutic response. Post a 2-month follow-up, the patient’s coagulation profile and factor II activity rebounded robustly, even breaching the upper echelons of the normal range³¹. Prospectively, deliberation will ensue to ascertain the potential incorporation of aspirin as a prophylactic measure against thrombosis³².

6. Conclusion

In summation, LAHS emerges as a rare disorder, presenting with a confluence of lupus anticoagulant and diminished prothrombin levels. This distinctive disorder is earmarked by recurrent episodes of both thrombosis and bleeding. This case study unfurls the maiden documented instance of adult-onset Lupus anticoagulant-hypoprothrombinemia syndrome (LAHS) juxtaposed with Sjögren’s syndrome. This revelation acts as a crucial beacon, signaling the medical fraternity to delve deeper into whether the pathogenesis, clinical features and prognosis of LAHS might oscillate depending on the underlying autoimmune disorder. Additionally, the timely diagnosis and initiation of the apt therapeutic regimen are paramount in amplifying the prognosis for such affected individuals.

7. FUNDING

Sichuan International Science and Technology Cooperation Project [2022YFH0023].

Reference

- Aldinger, J. P., Dobyms, T., Lam, K., & Han, J. K. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis. *Expert opinion on biological therapy*, 2021. 21(9), 1143–1149.
- Farber, C., Morey, R., Krimmer, M., Kurouski, D., & Rogovskyy, A. S. Exploring a possibility of using Raman spectroscopy for detection of Lyme disease. *Journal of biophotonics*, 2021. 14(5), e202000477.
- Hkiri, B., Béjaoui, A., Gharib, C., & AlNemer, H. A. Revisiting efficiency in MENA stock markets during political shocks: evidence from a multi-step approach. *Heliyon*, 2021. 7(9), e08028.
- Ko, Y. C., & Ong, H. N. Elderly man with abdominal pain. *Journal of the American College of Emergency Physicians open*, 2020. 1(5), 1110–1111.
- Hayrapetyan, D., & Khalimon, A. Y. Catalytic Nitrile Hydroboration: A Route to N,N-Diborylamines and Uses Thereof. *Chemistry, an Asian journal*, 2020. 15(17), 2575–2587.
- Chaytow, H., Sethw Hassan, I., Akbar, S., Popplewell, L., Dickson, G., & Chen, P. E. A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2. *Journal of neuroscience methods*, 364, 109357. 2021.
- Anderson, S. L., Wisnieski, L., Achilles, S. L., Wooton, K. E., Shaffer, C. L., & Hunt, J. A. The impact of gel fingernail polish application on the reduction of bacterial viability following a surgical hand scrub. *Veterinary surgery : VS*, 2021. 50(7), 1525–1532.
- Kyraleou, M., Herb, D., O'Reilly, G., Conway, N., Bryan, T., & Kilcawley, K. N. The Impact of Terroir on the Flavour of Single Malt Whisk(e)y New Make Spirit. *Foods (Basel, Switzerland)*, 2021. 10(2), 443.
- Höring, C., Conrad, M., Söldner, C. A., Wang, J., Sticht, H., Strasser, A., & Miao, Y. Specific Engineered G Protein Coupling to Histamine Receptors Revealed from Cellular Assay Experiments and Accelerated Molecular Dynamics Simulations. *International journal of molecular sciences*, 2021. 22(18), 10047.
- Hall, A., Chanteux, H., Ménochet, K., Ledecq, M., & Schulze, M. E. D. Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. *Journal of medicinal chemistry*, 2021. 64(10), 6413–6522.
- Reddy, P., Rivas, Y., Golowa, Y., KoganLiberman, D., Ho, S., Jan, D., & Ovchinsky, N. Novel Non-Surgical Interventions for Benign Inflammatory Biliary Strictures in Infants: A Report of Two Cases and Review of Current Pediatric Literature. *Pediatric gastroenterology, hepatology & nutrition*, 2019. 22(6), 565–570.
- Golinska, M. D., Włodarczyk-Biegun, M. K., Werten, M. W., Cohen Stuart, M. A., de Wolf, F. A., & de Vries, R. Dilute self-healing hydrogels of silk-collagen-like block copolypeptides at neutral pH. *Biomacromolecules*, 2014. 15(3), 699–706.
- Spitz, I. M., Croxatto, H. B., Lähteenmäki, P., Heikinheimo, O., & Bardin, C. W. Effect of mifepristone on inhibition of ovulation and induction of luteolysis. *Human reproduction (Oxford, England)*, 1994. 9 Suppl 1, 69–76.
- Milton, S., McIntosh, J., Yogaparan, T., Alphonse, P., Saya, S., Karnchanachari, N., Nguyen, P., Lau, P., Macrae, F., & Emery, J. Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study. *BMJ open*, 2021. 11(2), e042261.
- Ben-David, Y., Moraïs, S., Bayer, E. A., & Mizrahi, I. Rapid adaptation for fibre degradation by changes in plasmid stoichiometry within *Lactobacillus plantarum* at the synthetic community level. *Microbial biotechnology*, 2020. 13(6), 1748–1764.
- Ruta, F. L., Sternbach, A. J., Dieng, A. B., McLeod, A. S., & Basov, D. N. Quantitative Nanoinfrared Spectroscopy of Anisotropic van der Waals Materials. *Nano letters*, 2020. 20(11), 7933–7940.
- West J. C. Case law update. *Keys v. Alta Bates Summit Medical Center*, N. A140038 (Ct. App. Cal. February 23, 2015). *Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management*, 2016. 35(3), 48–49.
- Husted, M. M., Fournaise, A., Matzen, L., & Scheller, R. A. How to measure energy and protein intake in a geriatric department - A comparison of three visual methods. *Clinical nutrition ESPEN*, 2017. 17, 110–113.
- Zhang, Z. M., Bao, Y., Zhou, L. X., Zhao, R., Huang, J., & Liu, W. S. Feasibility of Diagnosing a Submucosal Nasopharyngeal Carcinoma by Endonasopharyngeal Ultrasound-Guided Transnasopharyngeal Needle Aspiration. *Chinese medical journal*, 2018. 131(12), 1506–1508.
- Gu, F. F., Hou, Q., Yang, H. H., Zhu, Y. Q., Guo, X. K., Ni, Y. X., & Han, L. Z. Characterization of *Staphylococcus aureus* Isolated from Non-Native Patients with Skin and Soft Tissue Infections in Shanghai. *PloS one*, 2015. 10(4), e0123557.
- Ohchi, F., Komazawa, N., Kadono, N., & Minami, T. (2014). A successful case of pediatric tracheal tube exchange utilizing gum-elastic bougie and videolaryngoscope. *Journal of pediatric intensive care*, 3(2), 79–80.
- Jallon, R., Imbeau, D., & de Marcellis-Warin, N. A process mapping model for calculating indirect costs of workplace accidents. *Journal of safety research*, 2011. 42(5), 333–344.
- Li, Z., Xie, P., Hu, R., Wang, D., Jin, H., Chen, H., Lin, C., & Liu, W. Observations of N2O5 and NO3 at a suburban environment in Yangtze river delta in China: Estimating heterogeneous N2O5 uptake coefficients. *Journal of environmental sciences (China)*, 2020. 95, 248–255.
- Yilmaz, R., Bayram, E., Ulukan, Ç., Altınok, M. K., & Akbostancı, M. C. Appendectomy History is not Related to Parkinson's Disease. *Journal of Parkinson's disease*, 2017. 7(2), 347–352.
- Sandor, B., Fintor, K., Reglodi, D., Fulop, D. B., Helyes, Z., Szanto, I.,

- Nagy, P., Hashimoto, H., & Tamas, A. Structural and Morphometric Comparison of Lower Incisors in PACAP-Deficient and Wild-Type Mice. *Journal of molecular neuroscience* : MN,2016. 59(2), 300–308.
26. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Turck, D., Bresson, J. L., Burlingame, B., Dean, T., Fairweather-Tait, S., Heinonen, M., Hirsch-Ernst, K. I., Mangelsdorf, I., McArdle, H. J., Naska, A., Neuhäuser-Berthold, M., Nowicka, G., Pentieva, K., Sanz, Y., Siani, A., Sjödin, A., Stern, M., Tomé, D., Vinceti, M., ... van Loveren, H. Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97. *EFSA journal*. European Food Safety Authority, 2017. 15(11), e05057.
 27. Lebina, L., Seatlholo, N., Taruberekera, N., Radebe, M., Kinghorn, A., Meyer, T., Mhazo, M., Otwombe, K., Hlongwane, K., Ringane, A., Koloane, N., Nkuta, M., Nkhwashu, N., Farirai, T., Kweza, P., Chidarikire, T., Shamu, S., Kufa, T., Puren, A., Martinson, N., ... Milovanovic, M. Feasibility of community-based HIV self-screening in South Africa: a demonstration project. *BMC public health*,2019. 19(1), 898.
 28. Gissi, D. B., Tarsitano, A., Leonardi, E., Gabusi, A., Neri, F., Marchetti, C., Montebugnoli, L., Foschini, M. P., & Morandi, L. Clonal analysis as a prognostic factor in multiple oral squamous cell carcinoma. *Oral oncology*, 2017. 67, 131–137.
 29. Ghosh, A. K., Tomaine, A. J., & Cantwell, K. E. Stereoselective Synthesis of Substituted Oxocene Cores by Lewis Acid Promoted Cyclization. *Organic letters*,2016. 18(3), 396–399.
 30. Algotar, A. M., Hsu, C. H., Chow, H. H., Dougherty, S. T., Babiker, H. M., Marrero, D. G., Abraham, I., Kumar, R., Ligibel, J. A., Courneya, K. S., Smith, T. E., Jones, P. A., Lopez, J. N., Niemi, G., Ramakumar, S., Hoy, R. D., Mack, C., & Thomson, C. A. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer. *Prostate cancer and prostatic diseases*, 2021. 24(3), 903–909.
 31. Wang, Y., Cao, X., Cheng, J., Yao, B., Zhao, Y., Wu, S., Ju, B., Zhang, S., He, X., & Niu, W. Cephalopod-Inspired Chromotropic Ionic Skin with Rapid Visual Sensing Capabilities to Multiple Stimuli. *ACS nano*, 2021. 15(2), 3509–3521.
 32. Del Zotto, G., Antonini, F., Azzari, I., Ortolani, C., Tripodi, G., Giacomelli, F., Cappato, S., Moretta, L., Ravazzolo, R., & Bocciardi, R. Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation. *Cytometry. Part B, Clinical cytometry*,2018. 94(4), 613–622.